Trial Profile
PROVE A Randomized Phase II Trial of Standard Carboplatin and Pegylated Liposomal Doxorubicin With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms PROVE
- Sponsors Wissenschaftlicher Service Pharma
- 06 Jun 2017 Primary endpoint (Progression-free survival (PFS) rate after 12 months.) has not been met, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology